Literature DB >> 7666665

Partial cystectomy for invasive bladder cancer.

N P Dandekar1, H B Tongaonkar, A V Dalal, J N Kulkarni, M R Kamat.   

Abstract

Thirty two patients--23 males and 9 females with a mean age of 52.5 years--underwent planned partial cystectomy for histologically proved muscle invasive bladder cancer. Twenty patients had transitional cell carcinoma and 12 had adenocarcinoma of the bladder. One patient had well-differentiated, 18 had moderately differentiated, and 13 had poorly differentiated tumours. The tumour size was < 2 cm in 7 patients, 2-4 cm in 19 patients, and > 4 cm in 6 patients. Patients with single primary muscle invasive tumours situated in the upper half of the bladder were considered eligible for partial cystectomy. The presence of multicentric urothelial disease, of dysplasia, or carcinoma-in-situ in bladder mucosa away from the tumour on multiple random punch biopsies was considered contraindications to partial cystectomy. All patients underwent partial cystectomy with bilateral pelvic lymphadenectomy. The tumour-free margins of resection were confirmed by intraoperative frozen section examination. The bladder was closed primarily in all patients, although three patients required re-implantation of the ureter. No patient received adjuvant radiation or chemotherapy. Five patients had pathological stage B1 (T2), 18 had B2 (T3A), and 9 had C (T3B) disease. No patient had metastatic pelvic lymph nodes. There was one postoperative death due to unrelated medical cause. Five patients had minor complications that resolved with conservative measures. All patients had adequate bladder capacity of > 250 cc at 6 months after surgery, and none had symptoms attributable to reduced bladder capacity. The overall actuarial survival was 80.1% at 5 years.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7666665     DOI: 10.1002/jso.2930600106

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

1.  Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy.

Authors:  Arjun Balar; Dean F Bajorin; Matthew I Milowsky
Journal:  Ther Adv Urol       Date:  2011-06

Review 2.  Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery?

Authors:  Eugene K Cha; Timothy F Donahue; Bernard H Bochner
Journal:  Urol Clin North Am       Date:  2015-02-28       Impact factor: 2.241

3.  Radical cystectomy versus alternative treatments for muscle-confined bladder cancer.

Authors:  A Tekin; F T Aki; H Ozen
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

4.  Impact of treatment delay in patients with bladder cancer managed with partial cystectomy in Quebec: a population-based study.

Authors:  Nader Fahmy; Armen Aprikian; Mohammed Al-Otaibi; Simon Tanguay; Jordan Steinberg; Suganthiny Jeyaganth; Moamen Amin; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2009-04       Impact factor: 1.862

5.  Practice patterns and recurrence after partial cystectomy for bladder cancer.

Authors:  Nader Fahmy; Armen Aprikian; Simon Tanguay; Salaheddin M Mahmud; Mohammed Al-Otaibi; Suganthiny Jeyaganth; Moamen Amin; Wassim Kassouf
Journal:  World J Urol       Date:  2009-10-14       Impact factor: 4.226

6.  Urothelial carcinoma management in elderly or unfit patients.

Authors:  Joaquim Bellmunt; Nicolas Mottet; Maria De Santis
Journal:  EJC Suppl       Date:  2016-03-22

7.  Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer.

Authors:  Jan Ebbing; Robin Colja Heckmann; Justin William Collins; Kurt Miller; Barbara Erber; Frank Friedersdorff; Tom Florian Fuller; Jonas Busch; Hans Helge Seifert; Peter Ardelt; Christian Wetterauer; Abolfazl Hosseini; Florian Jentzmik; Carsten Kempkensteffen
Journal:  Sci Rep       Date:  2018-05-30       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.